News & Press Releases
Press Release
September 3, 2025
Andelyn Biosciences and Tern Therapeutics Partner for Late-Stage Process Performance Qualification (PPQ) Manufacturing of AAV Gene Therapy for the Treatment of CLN2 Batten DiseaseAndelyn Biosciences and Tern Therapeutics Partner for Late-Stage Process Performance Qualification (PPQ) Manufacturing of AAV Gene Therapy for the Treatment of CLN2 Batten DiseasePress Release
May 12, 2025
Andelyn Biosciences Applies the AAV Curator® Platform to Deliver Novel Gene Therapy for an Ultra-Rare NEDAMSS Disease Patient 14-Months after DiagnosisAndelyn Biosciences Applies the AAV Curator® Platform to Deliver Novel Gene Therapy for an Ultra-Rare NEDAMSS Disease Patient 14-Months after DiagnosisPress Release
May 6, 2025
Andelyn Biosciences AAV Curator® Platform Used to Manufacture Clinical Grade Viral Vector for FDA-Authorized First-In-World Universal Donor CRISPR/AAV Transduced CAR-NK Cells.Andelyn Biosciences AAV Curator® Platform Used to Manufacture Clinical Grade Viral Vector for FDA-Authorized First-In-World Universal Donor CRISPR/AAV Transduced CAR-NK Cells.Press Release
February 18, 2025
Andelyn Biosciences Expands AAV Curator® Platform Offering to Include Stanton Lab CNS Capsids through a License Agreement from the Broad Institute of MIT and HarvardAndelyn Biosciences Expands AAV Curator® Platform Offering to Include Stanton Lab CNS Capsids through a License Agreement from the Broad Institute of MIT and HarvardPress Release
Press Release
August 6, 2024
Andelyn Biosciences Expands AAV Curator® Platform Offering to Include MyoAAV Plasmids through a License Agreement from the Broad Institute of MIT and HarvardAndelyn Biosciences Expands AAV Curator® Platform Offering to Include MyoAAV Plasmids through a License Agreement from the Broad Institute of MIT and HarvardPress Release
News
Press Release